Key facts
- SeqOne’s last known valuation is $101.4M (May 2025).
- It has raised $48.9M; the latest was Later Stage VC ($22.6M) in May 2025.
- Notable investors include Bpifrance, Elaia Partners, Supernova Invest, IRDI Capital Investissement, Omnes Capital — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for SeqOne
- ·The full record, as it builds
Funding rounds
No funding rounds for SeqOne are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SeqOne
Developer of a genomic analysis platform designed to offer analysis of genomic data. The company's platform provides advanced genomic analysis tools that manage the entire process of analysis from raw data to the final report, enabling healthcare professionals to analyze next-generation sequencing (NGS) genomic data better and cost-effectively.
- Sector
- Healthcare
- HQ
- Montpellier, France
- Founded
- 2017
- Employees
- 106
- Website
- seqone.com/
- Ownership
- Privately Held (backing)
SeqOne doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SeqOne shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SeqOne in its N-PORT filings yet. We sweep new filings monthly.